INVESTIGADORES
GIULIANELLI Sebastian Jesus
congresos y reuniones científicas
Título:
CDK4/6 inhibitors and antiprogestins: therapeutic combination in breast cancer experimental models with high levels of progesterone receptor isoform A
Autor/es:
PATACCINI, GABRIELA; VANZULLI, SILVIA; LANARI, CLAUDIA; GIULIANELLI, SEBASTIƁN
Lugar:
Buenos Aires
Reunión:
Simposio; Buenos Aires Breast Cancer Symposium; 2021
Resumen:
Luminal breast cancers are susceptible to an endocrine therapy. Palbociclib (PALBO), a CDK 4/6 inhibitor, is currently used in combination with endocrine therapy to treat advanced hormone receptor-positive breast cancer (BC). However, with time patients acquire resistance. Therefore, alternative therapies are required to reduce BC mortality. We have recently reported that BC patients with tumors expressing higher levels of isoform A of the progesterone receptor (PRA) than isoform B (PRB) may benefit from an antiprogestin treatment. The aim of this study was to evaluate the effect of PALBO in combination with the antiprogestin mifepristone (MFP) in the T47D BC model. We have already shown that MFP (10 nM) inhibits cells proliferation of T47D and T47D-YA cells (expressing only PRA) but not of T47D-YB cells (expressing only PRB). PALBO (100 nM) inhibited cell proliferation in the three cell lines. The combination of MFP and PALBO induced an additive inhibitory effect only in T47D and T47D-YA cells (p